Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer

BACKGROUND: Currently, no effective treatments exist for non-small cell lung cancer (NSCLC) after failure of gefitinib therapy. Pre-clinical studies have demonstrated that gefitinib-resistant NSCLC cells are more sensitive to irinotecan than parental cells, and that combined administration of irinot...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Horiike, A, Kudo, K, Miyauchi, E, Ohyanagi, F, Kasahara, K, Horai, T, Nishio, M
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2011
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208500/
https://ncbi.nlm.nih.gov/pubmed/21915126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.375
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi